Navigation Links
Hagfish slime as a model for tomorrow's natural fabrics
Date:11/28/2012

Nylon, Kevlar and other synthetic fabrics: Step aside. If new scientific research pans out, people may be sporting shirts, blouses and other garments made from fibers modeled after those in the icky, super-strong slime from a creature called the hagfish. The study appears in ACS' journal Biomacromolecules.

Lead author Atsuko Negishi, her supervisor Douglas S. Fudge and colleagues explain that petroleum is the raw material for making modern synthetics. Rising prices and the quest for more sustainable alternatives have led scientists to consider the possibilities of using protein-based raw materials, such as spider silk. Another candidate comes from the hagfish, an eel-like fish that produces a thick slime to protect itself against predators. A single Atlantic Hagfish can produce quarts of slime in seconds. It clogs the gills and may suffocate other fish. The slime consists of tens of thousands of remarkably strong threads, each 100 times thinner than a human hair. The scientists set out to investigate spinning spider-silk-like fibers from the proteins of these slime threads.

They developed a method for drawing hagfish slime thread proteins into fibers comparable to lab-made spider silk. It involved casting a thin self-supporting film of thread proteins on the surface of a salt solution, then grabbing it with forceps and lifting it upwards so it collapses into a single strand. The threads in hagfish slime, they indicate, might be models for synthetic fibers made from renewable, naturally occurring proteins.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. The slippery slope to slime: Overgrown algae causing coral reef declines
2. First model of how buds grow into leaves
3. Parkinsons disease stopped in animal model
4. New method for estimating parameters may boost biological models
5. Bone marrow transplant arrests symptoms in model of Rett syndrome
6. 3-D RNA modeling opens scientific doors
7. NCEAS researchers offer new ecological model for deep-water oil spills
8. Patel recognized with NSF Career Award for computer-modeling research on cell membranes
9. Model forecasts long-term impacts of forest land-use decisions
10. A cells first steps: Building a model to explain how cells grow
11. Computer model pinpoints prime materials for efficient carbon capture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... the way to go, if you are a primate crossing ... researchers have measured the energy required to navigate a forest ... in the trees. Their work was presented at the Society ... 2012. The findings help us to understand why ...
... discovered that recent climate change is causing leaves of some ... is the first of its kind in the world, highlights ... The results are published online today in the Royal ... analysed leaves from herbarium specimens of Narrow-leaf Hopbush ( Dodonaea ...
... resource developed at the San Diego Supercomputer Center ... is helping thousands of researchers worldwide unravel the ... among virtually every species on the planet. ... Infrastructure for Phylogenetic RESearch), created by SDSC researchers, ...
Cached Biology News:Shrinking leaves point to climate change 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 3
(Date:4/27/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the year ended December 31, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... did not provide the outcome management and investors ... at iCo Therapeutics", said Andrew Rae , ...
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... -- Haemonetics Corporation (NYSE: HAE ) today reported ... $226.5 million, down 6%.  Excluding currency impact, revenue ... reported a fourth quarter GAAP net loss of ... income, exclusive of transformation, restructuring and deal amortization ... and adjusted earnings per share were $0.47, up ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... CITY , May 6 /PRNewswire-FirstCall/ - Aeterna ... late-stage drug development company specialized in oncology and endocrinology, ... Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, ... ovarian cancer. AEZS-108 is currently in a Phase 2 ...
... Wheat aleurone is a novel wheat grain fraction ... clinical trials with ready-to-eat cereals and bread containing ... blood concentrations of tentatively beneficial compounds such as ... both associated with heart disease risk. It ...
... CHARLOTTE, N.C. , May 5 The untimely death ... addiction to the forefront of American media recently. The good news for ... pain relief. , , ... of those options is called radiofrequency thermocoagulation therapy. Used to treat pain ...
Cached Biology Technology:Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3Medication Doesn't Have to be the Answer to Pain; Southeast Pain Care Offers Pill-free Pain Relief 2
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: